Modulation of Cortisol Metabolism by the Growth Hormone Receptor Antagonist Pegvisomant in Patients with Acromegaly1
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Pegvisomant is a GH receptor antagonist and highly efficacious new treatment for acromegaly. The two isoenzymes of 11β-hydroxysteroid dehydrogenase are responsible for the interconversion of cortisol and its inactive metabolite cortisone. We demonstrated previously that the type I isoform, which is principally responsible for conversion of cortisone to cortisol, is partially inhibited by GH. The net activity of the enzyme can be measured by analysis of the urinary ratio of 11-hydroxy/11-oxo cortisol metabolites or of the urinary ratio of tetrahydrocortisol/tetrahydrocortisone [(tetrahydrocortisol + 5α-tetrahydrocortisol)/tetrahydrocortisone]. We studied the influence of pegvisomant on cortisol metabolism in patients with active acromegaly. Seven patients (four women and three men; median age, 58 yr; range, 39–72) were studied at baseline and again after a mean of 46 weeks of treatment. The mean insulin-like growth factor I (IGF-I) level at baseline fell from 939.7 ± 271.1 to 346.9 ± 379.0 ng/mL on 20 mg/day pegvisomant. The 11-hydroxy/11-oxo ratio increased from a pretreatment mean value of 0.61 ± 0.18 to 0.88 ± 0.20 (P < 0.02) and when the six patients in whom serum IGF-I normalized were considered separately, the change was from 0.62 ± 0.19 to 0.90 ± 0.21 (P < 0.04). The tetrahydrocortisols/tetrahydrocortisone ratio increased from a pretreatment mean value of 0.64 ± 0.21 to 0.98 ± 0.26 (P < 0.02) and in the six patients in whom serum IGF-I normalized, the ratio rose from 0.66 ± 0.23 to 1.01 ± 0.26 (P < 0.04). These data 1) indicate that blockade of GH action with pegvisomant in patients with acromegaly is associated with reversal of the inhibition of 11β-hydroxysteroid dehydrogenase and correction of cortisol metabolism, and 2) suggest that in active acromegaly, cortisol clearance is accelerated and that this is reversed by successful treatment. This is further evidence of the efficacy of pegvisomant in the management of acromegaly and has important implications for determining optimum glucocorticoid replacement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Urinary free cortisone and the assessment of 11β‐hydroxysteroid dehydrogenase activity in man
Palermo, M., Shackleton, C. H. L., Mantero, F., & Stewart, P. M. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00853.x · Cited by 276 · cited 1×
“We and others have previously demonstrated that GH does not alter the urinary free cortisol to cortisone ratio, indicating that the changes in Fm/Em and THF plus 5aTHF/THE ratios due to GH are specific to 11bHSD1 (1, 9 ).”
BackgroundGelding, S. V., Taylor, N. F., Wood, P. J., Noonan, K., Weaver, J. U., Wood, D. F., & Monson, J. P. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.3641180.x · Cited by 124
Self-citation
Cited by
11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
“This is supported by the observation that pegvisomant, a GH antagonist that increases endogenous GH but effectively blocks GH signal transduction and lowers IGF-I levels, reverses the reduction in the THF alloTHF/THE ratio seen in untreated acromegaly (30).”
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Gadelha, M. R., Kasuki, L., Lim, D. S. T., & Fleseriu, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00115 · Cited by 363
Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly
Kopchick, J. J., Parkinson, C., Stevens, E. C., & Trainer, P. J. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0022 · Cited by 352
Self-citationGlucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose Tissue
Seckl, J. R. (2004) · Recent Progress in Hormone Research · doi:10.1210/rp.59.1.359 · Cited by 239
“In humans with hypopituitarism and acromegaly, this effect may be important (Moore et al., 1999; Trainer et al., 2001; Tiosano et al., 2003).”
Modulation of glucocorticoid metabolism by the growth hormone – IGF‐1 axis
Agha, A., & Monson, J. P. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02763.x · Cited by 108
Self-citationGiavoli, C., Libé, R., Corbetta, S., Ferrante, E., Lania, A., Arosio, M., Spada, A., & Beck-Peccoz, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1114 · Cited by 97
11β-Hydroxysteroid dehydrogenase: unexpected connections
Walker, E. A., & Stewart, P. M. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(03)00134-6 · Cited by 72
Veldhuis, J. D., Bidlingmaier, M., Anderson, S. M., Evans, W. S., Wu, Z., & Strasburger, C. J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-011885 · Cited by 61
Impact of the GH-cortisol ratio on the age-dependent changes in body composition
Nass, R., & Thorner, M. O. (2002) · Growth Hormone & IGF Research · doi:10.1016/s1096-6374(02)00022-9 · Cited by 58
Metadata
- Authors
- Trainer, P. J., Drake, W. M., Perry, L. A., Taylor, N. F., Besser, G. M., & Monson, J. P.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-07-01
- Volume
- 86
- Issue
- 7
- Pages
- 2989-2992
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2021417305
- Cited by
- 72
- References
- 2
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.